Meet the Bionic Vision Technologies Executive Management Team

 

Ash Attia

Chief Executive Officer

Ash Attia, PhD, FAICD  Ash has more than 30 years of senior executive management experience in implantable devices and biotechnology. Prior to BVT, Ash held the position of Vice President Asia Pacific, the Middle East and Israel, at TransMedics Inc. Ash also held Vice President and Managing Director roles within several other major Australian and International medtech organizations such as Thoratec, St Jude Medical, Micromed, Syncardia, Ventracor, Biotronik, SulzerMedica and Telectronics. Ash has extensive experience in medical technology commercialization, general management, research and development, marketing, market entry strategies, regulatory and reimbursement across multiple geographies (USA, Asia Pacific and Europe). He is also a Fellow of the Australian Institute of Company Directors and has extensive governance experience being a Non-Executive Director on the board of ASX-listed Company DorsaVi for over 10 years.

Qualifications

BSc (E.Eng/Med Eng with Honors)
MSc (Med. Eng)
PhD (Med. Sc)
FAICD

Jul 2019 – present

  • 30+ years of senior executive management experience in implantable devices and biotechnology.
  • Vice President and Managing Director roles with global medical devices organizations including TransMedics, St. Jude Medical, Thoratec, Syncardia,Ventarcor, Biotronik, SulzerMedica, and Telectronics/Nucleus Group.
  • Extensive experience in Class III medical devices commercialization including market entry strategies, R&D, Clinical, Regulatory, Reimbursement, General Management and Global Expansion.

 

Brian Gordon

Chief Technology Officer

Brian Gordon, MBA  Brian Gordon joined BVT in January 2019 as Chief Technology Officer. Brian joined us from Cochlear Ltd where he had held various senior engineering roles including most recently the position of Senior Portfolio Manager, Implants. Brian was responsible for delivery of Cochlear’s new implant projects to market.

Qualifications

BEng (Electrical with Honors)
BCommerce (Marketing / Economics)
MBA
PMP

Jan 2019 – present

  • 20 years experience of new product development in implantable medical devices and the electronics industry.
  • Senior leadership roles at market leading companies including Cochlear & RØDE Microphones.
  • Recently the Senior Portfolio Manager at Cochlear responsible for delivery of new implantable systems to global market.
  • Extensive experience in bringing Class III medical devices to market in highly regulated environments.

 

 

Adrian Oates

Chief Operating Officer

Adrian Oates, PhD  Adrian joined BVT in March 2019 as Chief Operating Officer. Adrian has more than 25 years of senior executive experience in the medical device, in-vitro diagnostic, biological and pharmaceutical health care industries at major companies including Cochlear and CSL Behring.

Qualifications

BSc (Biochemistry/ Microbiology)
MSc (Biochemistry)
PhD (Medicine)

 

Mar 2019 – present

  • 25+ years experience of leadership roles in the medical device, in-vitro diagnostic, biological and pharmaceutical health care industries.
  • Vice President and Director level roles at global companies including Cochlear, CSL Behring and Universal Biosensors.
  • Extensive experience across quality, regulatory, clinical & operations in highly regulated environments including Class III implantable medical devices

Meet the Bionic Vision Technologies Board

The Board of Bionic Vision Technologies is responsible for oversight of the management of the company and providing strategic direction. The members of the Board have a great depth of experience in commercialization of medical technologies and corporate finance.

The Management of Bionic Vision Technologies is responsible for business operations including product development, regulatory and commercialization

 

Ergad Gold

Chairman

Ergad Gold, PhD  Ergad Gold is a Principal and Director of the Momentum venture capital group and has many years’ experience in product development and commercialisation spanning a wide range of technologies. He has worked extensively in industry, government and academia and for six years operated his own consulting practice specialising in technology management. Within the Momentum portfolio, Ergad is currently a Director of CR-X Pty Ltd and Retriever Communications Pty Ltd. He was formerly a Director of EnGeneIC Ltd, Panviva Pty Ltd and Biovend Pty Ltd. He is also a Director of the Cooperative Research Centre for Polymers and also serves on commercialisation advisory committees at the Florey Neurosciences Institute and the Bionics Institute.

Qualifications

BSc (Hons)
PhD

 

Ash Attia

Chief Executive Officer

Ash Attia, PhD, FAICD  Ash Attia has over 30 years of senior executive management experience in implantable devices and biotechnology. Prior to BVT, Ash held the position of Vice President Asia Pacific, the Middle East and Israel, at TransMedics Inc. Ash also held Vice President and Managing Director roles within several other major Australian and International medtech organizations such as Thoratec, St Jude Medical, Micromed, Syncardia, Ventracor, Biotronik, SulzerMedica and Telectronics. Ash has extensive experience in medical technology commercialization, general management, research and development, marketing, market entry strategies, regulatory and reimbursement across multiple geographies (USA, Asia Pacific and Europe). He is also a Fellow of the Australian Institute of Company Directors and has extensive governance experience being a Non-Executive Director on the board of ASX-listed Company DorsaVi for over 10 years.

Qualifications

BSc (E.Eng/Med Eng with Honors)
MSc (Med. Eng)
PhD (Med. Sc)
FAICD

 

Alastair Lam

Director

Alastair was the Founder of Synergy Group and responsible for formulating its overall corporate strategies and management directions. Mr. Lam served as a Non-Executive Director at Synergy Group Holdings International Ltd. from December 14, 2011 to December 19, 2016. Mr. Lam serves as a Director of Synergy Lighting Limited and Synergy Group Worldwide Limited. From 2001 to 2006, Mr. Lam was the accounting executive in Qualipak Manufacturing Limited, a then wholly owned subsidiary of Qualipak International Holdings Limited, a company listed on the Main Board of the Stock Exchange.

 

Alan Kwan

Director

Mr. Alan Kwan is the Executive Director of State Path Capital.
State Path is headed by executive director Alan Kwan and chaired by Alastair Lam, the nephew of Hong Kong’s richest person Li Ka-shing whose net worth is valued at nearly $US30 billion, according to Forbes.
Dianne Angus

 

Dianne Angus

Non-Executive Director

Dianne has worked as a senior executive within the biotechnology, pharmaceutical, agritech, medical device and healthcare sectors for over twenty years and currently serves as non-executive director with Neuren Pharmaceuticals Limited (ASX: NEU) and Imagion Biosystems (ASX: IBX). She has built competitive and differentiated product portfolios, from investment in innovative research and product development to commercialisation and market entry. Dianne has created many global industry partnerships to accelerate asset development, attract financing and provide reputational validation & endorsement. With eighteen years’ experience in ASX and NASDAQ listed companies, Dianne has expertise in corporate governance, capital raising and stakeholder engagement within the listed capital market sector. Dianne is a member of the Australian Institute of Company Directors and is a registered patent & trademark attorney.

Qualifications

B.Sc. Hons. (Zoology/Genetics)
M. Biotechnology (Chem Eng.)
Grad Dip. IP Law

Stuart Grimshaw

 

 

Stuart Grimshaw

Non-Executive Director

Mr. Grimshaw has a long and distinguished career in financial services. His most recent role was with Nadaq listed EZCORP which he joined in November 2014 as Executive Chairman and a member of the Board of Directors. Shortly thereafter he became Chief Executive Officer, remaining on the Board, taking control of the operational business, in February 2015. Prior to joining EZCORP, he was Managing Director and Chief Executive Officer of Bank of Queensland Limited (ASX: BOQ), a consumer banking and financial services institution with branches in every Australian state and territory taking them from a $1.2Bn market capitalization in 2012 to $4.3Bn in 2014. During his 30-year career in financial services, Mr. Grimshaw held a wide variety of other roles at various banking and finance companies. From 2009 to 2011, he was Chief Executive Officer of Caledonia Investments Pty Ltd. Prior to that, Mr. Grimshaw spent eight years at Commonwealth Bank of Australia, where he served as Group Executive, Premium Business Services (2006 to 2009), Group Executive, Wealth Management (2002 to 2006) and Chief Financial Officer (2001 to 2002). From 1991 to 2001, Mr. Grimshaw held a variety of roles at National Australia Bank (including Chief Executive Officer – Great Britain, and other executive roles in Credit, Institutional Banking, Corporate Financial Services and Global Business Financial Services). Mr. Grimshaw began his career at Australia and New Zealand Banking Group (1983 to 1991). Mr. Grimshaw represented New Zealand in Field Hockey at the 1984 Olympics and has a Bachelor of Commerce and Administration degree from Victoria University in Wellington, New Zealand and an MBA from Melbourne University. He has also completed the Program for Management Development at Harvard Business School. Mr. Grimshaw also served as non-executive chairman of the board of directors of Cash Converters International Limited.

Qualifications

B. Commerce and Administration
MBA

 

Brendan Case

Company Secretary

Brendan Case is the Managing Director of Case Governance. He is a Chartered Secretary, has a Masters of Commercial Law from The University of Melbourne and has degrees in both Economics and Finance. Brendan has more than 25 years of company secretarial, corporate governance and finance experience. He is a former Associate Company Secretary of National Australia Bank Limited. Brendan is currently the Company Secretary of three companies listed on the ASX and is a non-executive director of a number of private companies. Case Governance also provides services to organisations based offshore which have established Australian entities to conduct medical research in Melbourne. 

Qualifications

MComLaw (Melb)
BEc
CPA
FGIA
MAICD